EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Xeris Biopharma Holdings's enterprise value is $404.4 Mil.
Xeris Biopharma Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $163.9 Mil. Therefore, Xeris Biopharma Holdings's EV-to-Revenue for today is 2.47.
The historical rank and industry rank for Xeris Biopharma Holdings's EV-to-Revenue or its related term are showing as below:
XERS'
s EV-to-Revenue Range Over the Past 10 Years
Min: -24.42 Med: 5.57 Max: 179.06
Current: 2.47
During the past 8 years, the highest EV-to-Revenue of Xeris Biopharma Holdings was 179.06. The lowest was -24.42. And the median was 5.57.
XERS's EV-to-Revenue is ranked better than 73.81% of 1031
companies
in the Biotechnology industry
Industry Median: 7.58
vs XERS: 2.47
As of today (2024-04-19), Xeris Biopharma Holdings's stock price is $1.733.
Xeris Biopharma Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.19. Therefore, Xeris Biopharma Holdings's PS Ratio for today is 1.46.
Xeris Biopharma Holdings EV-to-Revenue Historical Data
The historical data trend for Xeris Biopharma Holdings's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Xeris Biopharma Holdings Annual Data
Trend
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-Revenue
64.15
12.06
7.09
2.33
2.94
Xeris Biopharma Holdings Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-Revenue
2.33
2.70
3.77
2.74
2.94
Competitive Comparison
For the Biotechnology subindustry, Xeris Biopharma Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeris Biopharma Holdings EV-to-Revenue Distribution
For the Biotechnology industry and Healthcare sector, Xeris Biopharma Holdings's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's EV-to-Revenue falls into.
Xeris Biopharma Holdings's current Enterprise Value is $404.4 Mil.
Xeris Biopharma Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $163.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xeris Biopharma Holdings's share price for today is $1.733.
Xeris Biopharma Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.19.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xeris Biopharma Holdings EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Xeris Biopharma Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Xeris Biopharma Holdings (Xeris Biopharma Holdings) Business Description
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XERS has been successfully added to your 